Reimbursement, Utilization, and 1-Year Survival Post-Allogeneic Transplantation for Medicare Beneficiaries With Acute Myeloid Leukemia

BACKGROUND: The economics of allogeneic hematopoietic cell transplantation (alloHCT) for older patients with acute myeloid leukemia (AML) affects clinical practice and public policy. To assess reimbursement, utilization, and overall survival (OS) up to 1 year post-alloHCT for Medicare beneficiaries...

Descripción completa

Detalles Bibliográficos
Autores principales: Mau, Lih-Wen, Meyer, Christa, Burns, Linda J, Saber, Wael, Steinert, Patricia, Vanness, David J, Preussler, Jaime M, Silver, Alicia, Leppke, Susan, Murphy, Elizabeth A, Denzen, Ellen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6845850/
https://www.ncbi.nlm.nih.gov/pubmed/31750417
http://dx.doi.org/10.1093/jncics/pkz048

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6845850/
https://www.ncbi.nlm.nih.gov/pubmed/31750417
http://dx.doi.org/10.1093/jncics/pkz048

Ejemplares similares